Notice of Change to Funds Available and Anticipated Number of Awards for RFA-FD-13-022 Postmarketing Surveillance of Generic Drug Usage and Substitution Patterns (U01)

Notice Number: NOT-FD-13-007

Key Dates
Release Date: May 17, 2013

Related Announcements
RFA-FD-13-022

Issued by
U.S. Food and Drug Administration (FDA)

Purpose

The purpose of this Notice is to change the Funds Available and Anticipated Number of Awards for RFA-FD-13-022.

Now Reads:


Funds Available and Anticipated Number of Awards

The number of awards is contingent upon FDA appropriations and the submission of a sufficient number of meritorious applications.

FDA/CDER intends to fund up to 1 award, corresponding up to $250,000 total costs, for fiscal year 2013.


Should Read:


Funds Available and Anticipated Number of Awards

The number of awards is contingent upon FDA appropriations and the submission of a sufficient number of meritorious applications.

FDA/CDER intends to fund up to $500,000 to this grant program in FY 2013.

It is anticipated that up to two (2) awards will be made, not to exceed $250,000 in total costs (direct plus indirect) per award.


Inquiries

Please direct all inquiries to:

Lisa Ko
Grants Management Specialist
U.S. Food and Drug Administration
Office of Acquisition and Grants Services
5630 Fishers Lane Room 2027
Rockville, MD 20857
TEL: 301-827-5095
FAX: 301-827-0505
EMAIL: Lisa.Ko@fda.hhs.gov